Real-world outcomes of cellular, acellular, and matrix-like products (CAMPs) in Stage 3 pressure injury ulcers: A matched Medicare claims analysis (2016–2024)
International Journal of Tissue Repair · 2026
DOI: 10.63676/dj8g4218 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Tissue Repair, 2026. Verfasst von William Tettelbach und 17 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Dekubitus
Abstract (Originalsprache)
Background
Stage 3 pressure injuries (PIs) are full-thickness wounds associated with high morbidity, frequent infection-related complications, and substantial healthcare utilization in adults with compromised mobility. Real-world outcomes of cellular, acellular, and matrix-like products (CAMPs) for Stage 3 PIs in Medicare populations have not been well characterized.
Methods
We conducted a retrospective, matched-cohort study using Medicare claims data (2016–2024). Stage 3 PI ulcer treatment episodes were constructed using a 90-day clean period (defined as ≥90 days without wound-related services) and a 90-day episode definition and evaluated in a hospital outpatient department (HOPD)/inpatient-only sample. Episodes receiving CAMPs (identified by Q- and A- Healthcare Common Procedure Coding System (HCPCS) codes) were matched 1:1 to standard-of-care (SOC) episodes (which included sharp debridement without CAMPs) using a prespecified set of exact and range-based covariates including demographics, comorbidity burden, PI location markers, and timing measures. Outcomes included episode characteristics, complications (including sepsis), healthcare utilization, costs, and mortality (death within 90 days of episode end). Two minimum-duration cohorts were analyzed (90 and 120 days).
Results
For the 90-day minimum cohort (n=7223 matched episodes per group), CAMP episodes had lower mean PI-associated spending ($36,397 vs $39,886; p=0.0003) and lower mean total all-cause spending ($46,905 vs $50,686; p=0.0006). Compared with SOC, CAMP episodes were associated with lower complications and healthcare resources utilization, including lower sepsis (26.1% vs 36.1%; p
Zitieren
APA
Tettelbach, W., Armstrong, D., Oropallo, A., Kelso, M. R., Tucker, T., Gooden, J., Kapp, D., Niezgoda, J., Alper, D., Morrison, L., Nolan, K., Low, M., Bohn, G., Davenport, T., Rogers, L., Desvigne, M., Robert, & William (2026). Real-world outcomes of cellular, acellular, and matrix-like products (CAMPs) in Stage 3 pressure injury ulcers: A matched Medicare claims analysis (2016–2024). International Journal of Tissue Repair. https://doi.org/10.63676/dj8g4218
Vancouver
Tettelbach W, Armstrong D, Oropallo A, Kelso MR, Tucker T, Gooden J, et al. Real-world outcomes of cellular, acellular, and matrix-like products (CAMPs) in Stage 3 pressure injury ulcers: A matched Medicare claims analysis (2016–2024). International Journal of Tissue Repair. 2026. doi:10.63676/dj8g4218
BibTeX
@article{Tettelbach2026,
author = {Tettelbach, William and Armstrong, David and Oropallo, Alisha and Kelso, Martha R and Tucker, Travis and Gooden, Justin and Kapp, Daniel and Niezgoda, Jeffrey and Alper, David and Morrison, Lynnette and Nolan, Kevin and Low, Mervin and Bohn, Gregory and Davenport, Thomas and Rogers, Lee and Desvigne, Michael and Robert and William},
title = {Real-world outcomes of cellular, acellular, and matrix-like products (CAMPs) in Stage 3 pressure injury ulcers: A matched Medicare claims analysis (2016–2024)},
journal = {International Journal of Tissue Repair},
year = {2026},
doi = {10.63676/dj8g4218}
}
EUVIMED